Abstract | OBJECTIVE: DESIGN: Ten micrograms per milliliter of TNIIIA2 were injected into the knee joint of mice (group II) to evaluate the induction of synovitis. The control group received an injection of phosphate buffered saline (group I). Synovitis was evaluated using synovitis score 2 and 4 weeks after injection. The ligaments of knee joints of mice were transected to make the osteoarthritis model. After transection, 10 µg/mL of TNIIIA2 was injected into the knee joint (group IV). The control group received an injection of phosphate buffered saline after transection (group III). Histologic examinations were made using hematoxylin and eosin and safranin-O staining at 2, 4, 8, and 12 weeks postoperatively. An in vitro study was also performed to determine the mechanism by which TNIIIA2 prevents cartilage degeneration. Human chondrocytes were isolated, cultured, and treated with TNIIIA2. The expressions of various mRNAs, including inflammatory cytokines, and anabolic and catabolic factors for cartilage were compared using real-time polymerase chain reaction. RESULTS: CONCLUSION: We demonstrated that TNIIIA2 could prevent cartilage degeneration without synovitis.
|
Authors | Tetsuya Hattori, Masahiro Hasegawa, Hironori Unno, Takahiro Iino, Fumio Fukai, Toshimichi Yoshida, Akihiro Sudo |
Journal | Cartilage
(Cartilage)
Vol. 13
Issue 2_suppl
Pg. 1367S-1375S
(12 2021)
ISSN: 1947-6043 [Electronic] United States |
PMID | 32204600
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
|
Topics |
- Animals
- Cartilage Diseases
(pathology)
- Cartilage, Articular
(pathology)
- Extracellular Matrix
(metabolism)
- Mice
- Peptides
(pharmacology)
- Tenascin
|